openPR Logo
Press release

Drug and cosmetics

10-11-2017 11:44 AM CET | Health & Medicine

Press release from: OMICS International Conferences

Drug and Cosmetics Conferences regards each one of the individuals to go to the On “Drug and Cosmetics” amidst October 17-October 18, 2018 in Toronto, Canada which melds brief keynote presentations, speaker talks, Exhibition, Symposia, Workshops. Drug and Cosmetics Congress is one of the meetings and conferences which will be visited by all the prestigious cosmetologists, Scientists, fiery inspectors, postgraduates, affiliations, business meanders under a solitary rooftop.

DRug and cosmetics

BLESSY MATHEW
Program coordinator
Phone +2018779344 Extn:- 5008

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Drug and cosmetics here

News-ID: 766257 • Views: 220

More Releases from OMICS International Conferences

Meet up with renowned Scientists at Canada’s Newest Renewable Energy Conferenc …
The aim of RENEWABLE ENERGY 2017 is to foster the new innovation and build momentum to translate ambitious renewable power targets to action on the ground. It’s a unique event where new applications and new ideas will be exchanged. The corporate, industries and academics will connect under one roof to find a global partner for partnership to explore their research work. This International conference is expected to facilitate discussions, presentations
CNS Disorders and Therapeutics 2016
We are pleased to invite you to the “2nd International Conference and Exhibition on Central Nervous System Disorders and Therapeutics” scheduled from December 05-07, 2016 in Dubai, UAE. For three days, you will experience about the effect of greater innovation in the field of CNS and Neurology with the theme, “Accelerate the Diagnosis, Prevention & Management of CNS disorders”. We would like to formally invite you to come and share

More Releases for Drug

Biologics Drug Discovery Market
2019-2025 Biologics Drug Discovery Market Report with Depth Analysis The biologics drug discovery involves target identification, hit-to-lead stage, lead identification and optimization. The report presents a comprehensive overview, market size, shares, and growth opportunities of Biologics Drug Discovery market by product type, application, key manufacturers and key regions. Request For Free report Sample -https://www.reportsmonitor.com/request_sample/306320 Scope of the Report: Furthermore, Biologics Drug Discovery Market report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers or
Opioid Antagonist Drug Market
The global market has been prognosticated to earn demand from popular types of products such as external use, oral and applications such as household and hospital. The Company has made available another publication in its Healthcare archive of market intelligence reports, which is titled “Global Opioid Antagonist Drug Market Research Report 2018.” While the threat of substitutes and technological risks could have an unfavorable impact on the global market, potential
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
International Drug-Drug Interaction (DDI) Workshop 2013 at Marbach Castle
Radolfzell, Germany, April 22nd 2013: The organization team of the International DDI Workshop announces the final programme of the DDI 2013 – 4th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions, which will take place from May 26th to 28th 2013 at Marbach Castle, Germany. More than 80 experts from 14 countries attended the DDI Workshop 2012. Based on the current